Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19
NCT ID: NCT04649918
Last Updated: 2021-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2020-11-25
2021-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Persistent dyspnea is a frequently described symptom after the acute phase of the disease. Coupled with reduced oxygen saturation, an increased risk of developing lung fibrosis has been observed. Specialized rehabilitation medicine (e.g. pulmonary rehabilitation) might counteract these long-term consequences and therefore seems to be a promising approach to treat long-term COVID-19 consequences.
Further, there is scarce evidence about COVID-19 specific rehabilitation contents. It was suggested to use treatment regimes in analogy to patients with idiopathic pulmonary fibrosis.
There is evidence that pulmonary rehabilitation improves physical performance, quality of life and reduces anxiety and depression symptoms in patients with idiopathic pulmonary fibrosis and other chronic respiratory diseases.
Since impairments related to idiopathic pulmonary fibrosis also play an important role in COVID-19, the aim of this study is to evaluate the short and medium-term effects of a standardized 3-week pulmonary rehabilitation program. The results will be analyzed within the two cohorts (mild/moderate and severe/critical COVID 19) as well as between the two cohorts for the primary outcome. Furthermore, the effects of pulmonary rehabilitation will be compared with a retrospective cohort of idiopathic pulmonary fibrosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
NCT04569266
Changes in Selected Function- and Participation-related Characteristics in Post-COVID Patients Following Pneumological Phase II Rehabilitation
NCT05496842
Two-year Efficacy of Three Exercise Rehabilitation Strategies on Dyspnea in Patients Who Presented With Secondary Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia
NCT05890560
Profiling Recovery of Those Discharged Into the Community With COVID-19
NCT04649957
Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis
NCT01772667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mild to moderate COVID 19
patients post-acute mild to moderate COVID 19
pulmonary rehabilitation
COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
severe to critical COVID 19
patients post-acute severe to critical COVID 19
pulmonary rehabilitation
COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pulmonary rehabilitation
COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schön Klinik Berchtesgadener Land
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Andreas Rembert Koczulla
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas R Koczulla, MD
Role: PRINCIPAL_INVESTIGATOR
Philipps University Marburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Schön Klinik Berchtesgadener Land
Schönau am Königssee, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID-Rehab
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.